No products in the cart.
Pre-made Etrolizumab benchmark antibody ( Whole mAb, anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-200
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Etrolizumab benchmark antibody (Whole mAb, anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn’s disease. It is a humanized monoclonal antibody against the ¦Â7 subunit of integrins ¦Á4¦Â7 and ¦ÁE¦Â7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgGl-heavy chain and ¦Ê-light chain frameworks; it is manufactured in CHO cells.
| Products Name (INN Index) | Pre-Made Etrolizumab biosimilar, Whole Mab: Anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody |
|---|---|
| INN Name | Etrolizumab |
| Target | ITGA4_ITGB7&ITGAE_ITGB7 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Genentech,Roche |
| Conditions Approved | NA |
| Conditions Active | Crohn's disease,Ulcerative colitis |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGA4_ITGB7&ITGAE_ITGB7 |
| Package |
Previous slide
Next slide
